Jonathan W. Riess

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib

  Cancer Research · 2026-04-17

• Abstract 1264: Limited apoptotic response in RBM10 wild type/deficient EGFR-mutant lung cancer patient-derived models overcome by combined EGFR and BCL-2/BCL-xL inhibition.

  Cancer Research · 2026-04-03

• Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

  Journal of the National Comprehensive Cancer Network · 2026-04-01 · 5 citations

• Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

  JTO Clinical and Research Reports · 2026-03-23

• Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  2026-03-16

• A phase 1 study of berzosertib (M6620, VX‐970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)

  Cancer · 2026-03-13

• Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

  Clinical Cancer Research · 2026-03-06

• 289 COPERNICUS: A Multinational Pragmatic Phase 2 Trial of Subcutaneous (SC) Amivantamab (Ami) in Common EGFR-Mutated (cEGFRm) NSCLC

  Lung Cancer · 2026-02-01

• Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i> -Altered Solid Tumors: Analysis of the RETgistry Global Consortium

  Clinical Cancer Research · 2026-01-15 · 1 citations

• Supplementary Figure S9 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Table S2 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Table S6 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Figure S2 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Figure S3 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Table S3 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11

• Supplementary Figure S5 from Comutations and KRAS&lt;sup&gt;G12C&lt;/sup&gt; Inhibitor Efficacy in Advanced NSCLC

  2025-12-11